个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Nengzhi Pang[1,4] * ; Jingxuan Shi[2,3] * ; Le Qin[2] * ; Aiming Chen[5] * ; Yuou Tang[1] ; Hainan Yang[1] ; Yufeng Huang[1] ; Qingde Wu[6] ; Xufeng Li[1] ; Bingjia He[1] ; Tianheng Li[1] ; Baoxia Liang[1] ; Jinglin Zhang[1] ; Bihui Cao[1] ; Manting Liu[1] ; Yunfei Feng[1] ; Xiaodie Ye[1] ; Xiaopei Chen[1] ; Lu Wang[1] ; Yu Tian[1] ; Hao Li[1] ; Junping Li[1] ; Hong Hu[1] ; Jingping He[1] ; Yuling Hu[1] ; Cheng Zhi[7] ; Zhaoyang Tang[8,9] ; Yibo Gong[10] ; Fangting Xu[11] ; Linfeng Xu[12] ; Weijun Fan[13] ; Ming Zhao[13] ; Deji Chen[1] ; Hui Lian[1] ; Lili Yang[4] ; Peng Li[2] ; Zhenfeng Zhang[1] ;
机构： [1]Department of Radiology.Translational Medicine Center and GuangdongProvincial Education Department Key Laboratory of Nano‑ImmunoregulationTumor Microenvironment, the Second Affiliated Hospital of Guangzhou MedicalUniversity, Guangzhou, Guangdong, China [2]Key Laboratory of RegenerativeBiology, Guangdong Provincial Key Laboratory of Stem Cell and RegenerativeMedicine, Center for Cell Regeneration and Biotherapy, GuangzhouInstitutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou,China [3]University of Chinese Academy of Science, Beijing 100049,China [4]Department of Nutrition.Guangdong Provincial Key Laboratoryof Food, School of Public Health, Sun Yat-Sen University, Guangzhou, Guangdong,China [5]Department of Radiology, Qianjiang Central Hospital, Qianjiang,Hubei, China [6]Department of Radiology, Shunde Chinese Medicine Hospital,The Affiliated Hospital of Traditional Chinese Medicine University of Guangzhou,Foshan, China [7]Department of Pathology, The Second Affiliated Hospitalof Guangzhou Medical University, Guangzhou, Guangdong, China [8]GuangdongZhaotai Cell Biology Technology Ltd.,Guangzhou, China [9]GuangdongZhaotai InVivo Biomedicine Co.Ltd.,Guangzhou, China [10]The Second XiangyaHospital, Central South University, Changsha, China [11]Xiangya Hospital,Central South University, Changsha, China [12]Department of InterventionalRadiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou,China [13]Minimally Invasive Interventional Division.Department of MedicalImaging and Interventional Radiology.State Key Laboratory of Oncologyin South China, Sun Yat-Sen University Cancer Center, Guangzhou, China
出处：
DOI： 10.1186/s13045-021-01128-9
ISSN：

关键词： CAR-T cell IL-7 CCL19 Glypican-3 Mesothelin Pancreatic carcinoma Hepatocellular carcinoma Complete response

摘要：
Although chimeric antigen receptor (CAR)-engineered T cells have shown great success in the treatment of B cell malignancies, this strategy has limited efficacy in patients with solid tumors. In mouse CAR-T cells, IL-7 and CCL19 expression have been demonstrated to improve T cell infiltration and CAR-T cell survival in mouse tumors. Therefore, in the current study, we engineered human CAR-T cells to secrete human IL-7 and CCL19 (7 × 19) and found that these 7 × 19 CAR-T cells showed enhanced capacities of expansion and migration in vitro. Furthermore, 7 × 19 CAR-T cells showed superior tumor suppression ability compared to conventional CAR-T cells in xenografts of hepatocellular carcinoma (HCC) cell lines, primary HCC tissue samples and pancreatic carcinoma (PC) cell lines. We then initiated a phase 1 clinical trial in advanced HCC/PC/ovarian carcinoma (OC) patients with glypican-3 (GPC3) or mesothelin (MSLN) expression. In a patient with advanced HCC, anti-GPC3-7 × 19 CAR-T treatment resulted in complete tumor disappearance 30 days post intratumor injection. In a patient with advanced PC, anti-MSLN-7 × 19 CAR-T treatment resulted in almost complete tumor disappearance 240 days post-intravenous infusion. Our results demonstrated that the incorporation of 7 × 19 into CAR-T cells significantly enhanced the antitumor activity against human solid tumor. Trial registration: NCT03198546. Registered 26 June 2017, https://clinicaltrials.gov/ct2/show/NCT03198546?term=NCT03198546&draw=2&rank=1.© 2021. The Author(s).

基金：
National Natural Science Foundation of China (No. 81672276 to Z. Z.; No. 81961128003 and 81972672 to P. L.; No. 81872613 and 81573142 to L. Y.; No. 81872069 to H. Y.),Guangzhou Science and Technology program (No. 201803010038 to Z. Z.); Strategic Priority Research Program of the Chinese Academy of Sciences (No. XDB19030205 and XDA12050305 to P. L.); The National Major Scientific and Technological Special Project for “Significant New Drugs Development (No. 2018ZX090201002-005); Guangdong provincial Significant New Drugs Development (No. 2019B020202003 to P. L.); Guangdong Special Support Program (No. 2017TX04R102 to P. L.); Guangzhou Science and Technology Plan Project (No. 201907010042 and 2020B1212060052 to P. L.); Frontier Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory (No. 2018GZR110105003 to P. L.); Science and Technology Planning Project of Guangdong province, China (No. 2017B030314056 to P. L.); a grant from the University Grants Committee / Research Grants Council of the Hong Kong Special Administrative Region, China (No. AoE/M-401/20 to P. L.).
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类 | 1 区 医学
小类 | 2 区 血液学 2 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 血液学 1 区 肿瘤学
JCR分区：
出版当年[2019]版：
Q1 HEMATOLOGY Q1 ONCOLOGY
最新[2023]版：
Q1 HEMATOLOGY Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者：
第一作者机构： [1]Department of Radiology.Translational Medicine Center and GuangdongProvincial Education Department Key Laboratory of Nano‑ImmunoregulationTumor Microenvironment, the Second Affiliated Hospital of Guangzhou MedicalUniversity, Guangzhou, Guangdong, China [4]Department of Nutrition.Guangdong Provincial Key Laboratoryof Food, School of Public Health, Sun Yat-Sen University, Guangzhou, Guangdong,China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Nengzhi Pang,Jingxuan Shi,Le Qin,et al.IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.[J].JOURNAL OF HEMATOLOGY & ONCOLOGY.2021,14(1):doi:10.1186/s13045-021-01128-9.
APA：
Nengzhi Pang,Jingxuan Shi,Le Qin,Aiming Chen,Yuou Tang...&Zhenfeng Zhang.(2021).IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin..JOURNAL OF HEMATOLOGY & ONCOLOGY,14,(1)
MLA：
Nengzhi Pang,et al."IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.".JOURNAL OF HEMATOLOGY & ONCOLOGY 14..1(2021)

相关文献

[1]Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma. [2]Tumor buster-where will the CAR-T cell therapy 'missile' go? [3]CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin's Lymphoma. [4]Propofol-induced miR-219-5p inhibits growth and invasion of hepatocellular carcinoma through suppression of GPC3-mediated Wnt/β-catenin signalling activation. [5]Association of the collagen signature with pathological complete response in rectal cancer patients [6]Nomogram for predicting pathological complete response to neoadjuvant chemotherapy in patients with advanced gastric cancer [7]Comparing Laparoscopic and Open Surgery for Pancreatic Carcinoma [8]无蒂型外生性肝癌的螺旋CT诊断 [9]A refractory case of CDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case report. [10]Hepatocellular carcinoma and hepatitis B surface protein

资源点击量：2022 今日访问量：0 总访问量：648 更新日期：2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持：重庆聚合科技有限公司 地址：广州市越秀区大德路111号